Advanced manufacturing of a bioprosthetic collagen heart valve - cardiovascular disease is a leading cause of death in the US, europe and japan and is comprised of a wide range of pathologies
Ended Project Grant Awarded Last action
- Award ID
- R43HL154956
- Recipient
-
Fluidform Bio, Inc. UEI KGL7K51B52Y5
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $255,369
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Place of performance
- Massachusetts, USA
Award details come from USAspending.gov.
Description
One of the most common procedures is heart valve replacement and is required when the valve fails due to regurgitation or is unable to open fully during the cardiac cycle. Causes include congenital defects, calcification and prolapse, but regardless of origin there are limited options to repair valves and surgical treatments are focused primarily on replacement. IT is estimated that each year more than 150,000 patients receive heart valve replacements at a mean cost of ~$200,000 per procedure, corresponding to >$30B cost to the healthcare system. The heart valve market has continued to grow over the past decade due to advances in surgical and minimally-invasive technologies associated with heart valve placement. However, current valves represent some compromise in fit, biological performance, durability and surgical procedure, with unique advantages and disadvantages associated with current mechanical and bioprosthetic heart valves. In this proposal our objective is to develop a new bioprosthetic heart valve using advanced manufacturing approaches that has the durability of mechanical valves, the non-thrombogenicity of biologic valves, the soft deformability for minimally-invasive transcatheter delivery, and the ability to custom fit the anatomy of any patient. To do this fluidform, INC in collaboration with carnegie mellon university will develop a new freeform reversible embedding of suspended hydrogels (FRESH) 3D printed heart valve using collagen type I that recreates the laminar and anisotropic extracellular matrix (ECM) architecture in native valves. Our preliminary data shows that FRESH 3D printing can be used to manufacture functional TRI-leaflet heart valves entirely from collagen and can support physiologic flow rates and pressure for short periods of time. Here we will improve valve performance by recreating the collagen fiber arrangement and mechanical properties in native valve leaflets via two research aims. First, we will demonstrate that FRESH 3D printing of collagen type I can recreate the collagen fiber architecture in the different layers of the native aortic valve leaflets with…
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $255,369 |
Quick answers
Who received award R43HL154956?
R43HL154956 was awarded to Fluidform Bio, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on March 24, 2021.
How much is award R43HL154956 worth?
$255,369 has been obligated on R43HL154956.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award